Refine
Has Fulltext
- yes (12)
Is part of the Bibliography
- yes (12)
Document Type
- Journal article (12)
Language
- English (12)
Keywords
- multiple myeloma (5)
- CXCR4 (4)
- PET (3)
- medicine (3)
- positron emission tomography (3)
- theranostics (3)
- FDG (2)
- PRRT (2)
- bone disease (2)
- molecular imaging (2)
- 177Lu (1)
- Antibodies (1)
- Arginine (1)
- CXCR4/SDF-1 (1)
- FDG PET/CT (1)
- Hyperkalaemia (1)
- Lysine (1)
- MAG3 (1)
- Myeloma cells (1)
- Myelomas (1)
- NET (1)
- PET/CT (1)
- Positron emission tomography (1)
- [\(^{68}\)Ga] pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{68}\)Ga-Pentixafor (1)
- adenocarcinoma of the lung (1)
- autologous transplantation (1)
- biosynthesis (1)
- bone marrow cells (1)
- cancer (1)
- cancer treatment (1)
- cell staining (1)
- cells (1)
- chemokine receptor (1)
- chemokine receptor-4 (1)
- collagens (1)
- esophagogastric junction (1)
- experience (1)
- extracellular matrix (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- imaging (1)
- imaging techniques (1)
- immunostaining (1)
- in vivo imaging (1)
- involvement (1)
- lesions (1)
- lung and intrathoracic tumors (1)
- macrophages (1)
- magnetic resonance imaging (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- microglial cells (1)
- neuroendocrine tumor (1)
- pleural mesothelioma (1)
- positron emission tomography/computed tomography (1)
- pulmonary imaging (1)
- radionuclide therapy (1)
- renal scintigraphy (1)
- secondary lung tumors (1)
- somatostatin (1)
- stem-cell transplantation (1)
- survival (1)
- trachea (1)
- treatment response (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (12) (remove)
\(^{11}\)C-methionine-PET in multiple myeloma: a combined study from two different institutions
(2017)
\(^{11}\)C-methionine (MET) has recently emerged as an accurate marker of tumor burden and disease activity in patients with multiple myeloma (MM). This dual-center study aimed at further corroboration of the superiority of MET as positron emission tomography (PET) tracer for staging and re-staging MM, as compared to \(^{18}\)F-2`-deoxy-2`-fluoro-D-glucose (FDG).
78 patients with a history of solitary plasmacytoma (n=4), smoldering MM (SMM, n=5), and symptomatic MM (n=69) underwent both MET- and FDG-PET/computed tomography (CT) at the University Centers of Würzburg, Germany and Navarra, Spain. Scans were compared on a patient and on a lesion basis. Inter-reader agreement was also evaluated. In 2 patients, tumor biopsies for verification of discordant imaging results were available.
MET-PET detected focal lesions (FL) in 59/78 subjects (75.6%), whereas FDG-PET/CT showed lesions in only 47 patients (60.3%; p<0.01), accordingly disease activity would have been missed in 12 patients. Directed biopsies of discordant results confirmed MET-PET/CT results in both cases.
MET depicted more FL in 44 patients (56.4%; p<0.01), whereas in two patients (2/78), FDG proved superior. In the remainder (41.0%, 32/78), both tracers yielded comparable results. Inter-reader agreement for MET was higher than for FDG (κ = 0.82 vs κ = 0.72).
This study demonstrates higher sensitivity of MET in comparison to standard FDG to detect intra- and extramedullary MM including histologic evidence of FDG-negative, viable disease exclusively detectable by MET-PET/CT. MET holds the potential to replace FDG as functional imaging standard for staging and re-staging of MM.
Development of predictable in vitro tumor models is a challenging task due to the enormous complexity of tumors in vivo. The closer the resemblance of these models to human tumor characteristics, the more suitable they are for drug-development and –testing. In the present study, we generated a complex 3D lung tumor test system based on acellular rat lungs. A decellularization protocol was established preserving the architecture, important ECM components and the basement membrane of the lung. Human lung tumor cells cultured on the scaffold formed cluster and exhibited an up-regulation of the carcinoma-associated marker mucin1 as well as a reduced proliferation rate compared to respective 2D culture. Additionally, employing functional imaging with 2-deoxy-2-[\(^{18}\)F]fluoro-D-glucose positron emission tomography (FDG-PET) these tumor cell cluster could be detected and tracked over time. This approach allowed monitoring of a targeted tyrosine kinase inhibitor treatment in the in vitro lung tumor model non-destructively. Surprisingly, FDG-PET assessment of single tumor cell cluster on the same scaffold exhibited differences in their response to therapy, indicating heterogeneity in the lung tumor model. In conclusion, our complex lung tumor test system features important characteristics of tumors and its microenvironment and allows monitoring of tumor growth and -metabolism in combination with functional imaging. In longitudinal studies, new therapeutic approaches and their long-term effects can be evaluated to adapt treatment regimes in future.